Ed Heslop joins Quadrant Biosciences as President of Viral Testing Division

SYRACUSE, NY, December 15, 2020 -- Quadrant Biosciences Inc., a developer of epigenetic diagnostic tools, announced that Ed Heslop has assumed the role of President of its recently created viral testing division, Quadrant Viral Testing LLC (“Quadrant Viral”). Quadrant Viral is a wholly owned subsidiary of Quadrant Biosciences established to manage wastewater surveillance of COVID-19, and other infectious diseases, in municipalities, nursing homes, colleges, office buildings and other communities. Mr. Heslop will be primarily responsible for spearheading the growth of Quadrant’s wastewater surveillance business.

Mr. Heslop has 40 years of entrepreneurial experience in the venture, non-medical life science industry. Prior to joining Quadrant, he was a founding member of businesses in agricultural production, development of rapid detection of carcinogens, innovative wastewater treatment, and climate change. He is an Executive in Residence at Cornell’s McGovern Center for Venture Life Sciences along with holding both a B.S. and M.S. from Cornell University.

"Ed is a great addition to our team,” said Richard Uhlig, Founder and CEO of Quadrant Biosciences. “He brings a wealth of entrepreneurial experience and strategic thinking to the table, and I’m confident he will play a critical role in the success of our wastewater surveillance business. Although our focus is currently on COVID-19 applications, we expect Quadrant Viral Testing to expand into testing other pathogens in the near future.”

“Having watched the development of Quadrant from the beginning I'm well aware of the vision and talents of the team,” said Mr. Heslop. “Seeing how they pivoted to focus their skills to develop one of the best in the world surveillance programs for COVID-19 monitoring is extremely impressive. When the time came I jumped at the opportunity to join the team.”

Since August, Quadrant has been involved in a pilot study funded by New York State to support wastewater testing in multiple municipalities and universities across the state. The aim of the study was to assess the efficacy of wastewater surveillance as an early warning system for identifying the relative prevalence of the SARS-CoV-2 virus in these larger populations. Following the successful completion of that study (documenting the ability to detect 1 infectious person in over 10,000), the company has been actively expanding the testing through its Quadrant Viral subsidiary to include additional universities, nursing homes, manufacturing, and communities. 

For inquiries about wastewater testing, please contact us at wastewater@quadrantbiosciences.com

For all general inquiries, contact us at info@quadrantbioscineces.com


Quadrant Biosciences is a life science company developing functional assessments and epigenetic diagnostic solutions for large-scale health issues. The company has entered into collaborative research relationships with a number of institutions including SUNY Upstate Medical University and Penn State University to explore and develop novel biomarker technologies with a focus on Autism Spectrum Disorder, concussion, and Parkinson's disease. Recently, it has leveraged its expertise in RNA analysis to address the COVID-19 pandemic. Quadrant participates in the Start-up NY program, a New York State economic development program. For more information about Quadrant, please visit www.quadrantbiosciences.com.